|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-7-28
|
|
pubmed:abstractText |
The influence of renal function on tenofovir pharmacokinetics was investigated in 193 human immunodeficiency virus (HIV)-infected patients by the use of a population approach performed with the nonlinear mixed effects modeling program NONMEM. Tenofovir pharmacokinetics was well described by a two-compartment open model in which the absorption and the distribution rate constants are equal. Typical population estimates of apparent central distribution volume (V(c)/F), peripheral distribution volume (V(p)/F), intercompartmental clearance (Q/F), and plasma clearance (CL/F) were 297 +/- 28.5 [corrected] liters, 848 +/- 209 [corrected] liters, 80 +/- 15 [corrected] liters/h and 50.5 +/- 3.1 [corrected] liters/h, respectively. Apparent plasma clearance was related to body weight/serum creatinine ratio (BW/S(CR)) and to the existence of a tubular dysfunction. Concomitant treatment with lopinavir/ritonavir was found to decrease tenofovir clearance. Individual Bayesian estimates of CL/F were used to calculate the tenofovir area under the concentration-time curve from time zero to 24 h (AUC(0-24)). In patients without tubular dysfunction, AUC(0-24) values markedly decreased from 6.7 to 1.4 mg . h/liter for BW/S(CR) increasing from 0.44 to 1.73. The relevance of a dosage adjustment based on BW/S(CR) should be further evaluated.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-10215174,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-11557462,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-11994051,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-1244564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-15076241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-15096814,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-15217303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-15673751,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-15735448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-3373416,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-4748282,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16048948-9736567
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
pubmed-author:DupinNicolasN,
pubmed-author:JaffrayPatrickP,
pubmed-author:JullienVincentV,
pubmed-author:KrivineAnneA,
pubmed-author:LescoatAnneA,
pubmed-author:Lillo-Le LouetAgnèsA,
pubmed-author:MoachonLaurenceL,
pubmed-author:PonsGérardG,
pubmed-author:ReyElisabethE,
pubmed-author:SalmonDominiqueD,
pubmed-author:TréluyerJean-MarcJM,
pubmed-author:UrienSaïkS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3361-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16048948-Adenine,
pubmed-meshheading:16048948-Adolescent,
pubmed-meshheading:16048948-Adult,
pubmed-meshheading:16048948-Aged,
pubmed-meshheading:16048948-Anti-HIV Agents,
pubmed-meshheading:16048948-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:16048948-Area Under Curve,
pubmed-meshheading:16048948-Bayes Theorem,
pubmed-meshheading:16048948-Female,
pubmed-meshheading:16048948-HIV Infections,
pubmed-meshheading:16048948-HIV-1,
pubmed-meshheading:16048948-Humans,
pubmed-meshheading:16048948-Kidney Function Tests,
pubmed-meshheading:16048948-Male,
pubmed-meshheading:16048948-Metabolic Clearance Rate,
pubmed-meshheading:16048948-Middle Aged,
pubmed-meshheading:16048948-Models, Biological,
pubmed-meshheading:16048948-Phosphonic Acids,
pubmed-meshheading:16048948-Reverse Transcriptase Inhibitors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
|
|
pubmed:affiliation |
Service de Pharmacologie Clinique, Hôpital Cochin-Saint-Vincent-de-Paul, 74-82 Avenue Denfert-Rochereau, 75674 Paris Cedex 14, France. Vincent.jullien@svp.aphp.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
